Roche stock price in focus: Goldman flips to neutral as ROG heads into Jan. 29 results
Roche shares closed up 0.93% at 348.90 francs Friday after Goldman Sachs raised its rating to neutral and boosted its price target to 365 francs, citing lower-risk clinical catalysts in 2026. UBS lifted its target to 384 francs, while Deutsche Bank held at 325. The SMI fell 0.5%. Swiss markets reopen Monday.